Sitemap
Glycotest

Our Company   

Our Company

Glycotest Diagnostics is developing unique and non-invasive blood tests for the large populations at risk of developing liver cancers and fibrosis-cirrhosis. Our technology could revolutionize care and treatment for groups at risk due to chronic liver disease—both people with viral hepatitis (chronic hepatitis B and C infections) and the rapidly growing population with non-viral hepatitis due to obesity and metabolic disease. Over 25 million people in the US, 800 million worldwide, and another 1.2 billion in jeopardy due to fatty liver disease may benefit from Glycotest’s products.


Based in the Philadelphia, Pennsylvania area and founded in 2012, Glycotest has exclusive worldwide rights to the use of over 50 patented serum glycoprotein biomarkers whose sugar structures are altered in liver cancers and fibrosis-cirrhosis by the abnormal attachment of the monosaccharide fucose. In addition, Glycotest owns the rights to proprietary assay technology that has been optimized for the measurement of these glycoproteins using engineered recombinant lectins. Glycotest’s technology was developed by two experts in the fields of liver disease and glycobiology—Professors Timothy Block and Anand Mehta at Drexel University College of Medicine and the Baruch S. Blumberg Institute.

Key features of Glycotest’s technology:

bollet
Exploits unique disease signal chemistry (glycoprotein fucosylation) present in liver cancers and fibrosis-cirrhosis but absent in healthy individuals
bollet
Incorporated into highly promising biomarker panels
bollet
Focused on the detection of potentially curable early-stage disease
bollet
May outperform currently available serum biomarkers, such as AFP
bollet
Targeting the worldwide liver cancer threat that kills more than 700,000 people annually and is the fastest growing cause of cancer death in the US